Scholarlink

Background <p>Inflammatory bowel disease (IBD) represents major global health challenges, but current treatments often are limited by efficacy loss, infection risks, and disruption of gut homeostasis. Novel therapies are needed to actively promote mucosal repair and restore immune balance.</p> Results <p>This study develops a nano-biotherapeutic by conjugating extracellular vesicles derived from <i>Bletilla striata</i> (BEVs) with the probiotic <i>Escherichia coli</i> Nissle 1917 (EcN) via supramolecular assembly. BEVs contained protocatechualdehyde as a key bioactive metabolite to suppress M1 macrophage polarization and reactive oxygen species (ROS) production. EcN@BEVs treatment significantly restored epithelial barrier integrity with the upregulated expression of ZO-1 and Occludin, and reversed microbiota dysbiosis by increasing the Firmicutes/Bacteroidota ratio. single-cell RNA sequencing (scRNA-seq) and invasion-adhesion-directed expression sequencing (INVADE-seq) analyses confirmed that EcN@BEVs promoted a shift from pro-inflammatory to anti-inflammatory macrophage phenotypes and reduced intracellular bacterial invasion.</p> Conclusions <p>The EcN@BEVs complex demonstrates significant therapeutic potential for colitis through a multi-faceted mechanism involving enhanced probiotic delivery, direct anti-inflammatory action, gut microbiota restoration, and mucosal immunity reprogramming. This study presents a promising integrated nanotherapeutic strategy for IBD treatment under cross-species collaboration.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bletilla striata-derived extracellular vesicles armed probiotic by supramolecular assembly ameliorates colitis via macrophage modulation and microbiota restoration

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月1日

查看全文
  • Weiliang Hou,
  • Kaiwen Sheng,
  • Minxin Gao,
  • Bing Liu,
  • Hao Wang,
  • Xu Li,
  • Yunjie Shi

摘要

Background

Inflammatory bowel disease (IBD) represents major global health challenges, but current treatments often are limited by efficacy loss, infection risks, and disruption of gut homeostasis. Novel therapies are needed to actively promote mucosal repair and restore immune balance.

Results

This study develops a nano-biotherapeutic by conjugating extracellular vesicles derived from Bletilla striata (BEVs) with the probiotic Escherichia coli Nissle 1917 (EcN) via supramolecular assembly. BEVs contained protocatechualdehyde as a key bioactive metabolite to suppress M1 macrophage polarization and reactive oxygen species (ROS) production. EcN@BEVs treatment significantly restored epithelial barrier integrity with the upregulated expression of ZO-1 and Occludin, and reversed microbiota dysbiosis by increasing the Firmicutes/Bacteroidota ratio. single-cell RNA sequencing (scRNA-seq) and invasion-adhesion-directed expression sequencing (INVADE-seq) analyses confirmed that EcN@BEVs promoted a shift from pro-inflammatory to anti-inflammatory macrophage phenotypes and reduced intracellular bacterial invasion.

Conclusions

The EcN@BEVs complex demonstrates significant therapeutic potential for colitis through a multi-faceted mechanism involving enhanced probiotic delivery, direct anti-inflammatory action, gut microbiota restoration, and mucosal immunity reprogramming. This study presents a promising integrated nanotherapeutic strategy for IBD treatment under cross-species collaboration.

Graphical Abstract